Page last updated: 2024-09-04

dx 8951 and Cholangiocarcinoma

dx 8951 has been researched along with Cholangiocarcinoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abou-Alfa, GK; Becerra, CR; De Jager, R; Eckhardt, SG; Feit, K; Kelsen, DP; O'Reilly, EM; Patt, YZ; Rowinsky, EK; Schwartz, GK; Sharma, S; Siegel, E	1

Trials

1 trial(s) available for dx 8951 and Cholangiocarcinoma

Article	Year
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. American journal of clinical oncology, 2005, Volume: 28, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Area Under Curve; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Drug Administration Schedule; Female; Gallbladder Neoplasms; Half-Life; Humans; Male; Middle Aged; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome	2005

Article

Year

A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.

American journal of clinical oncology, 2005, Volume: 28, Issue:4

Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Area Under Curve; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Drug Administration Schedule; Female; Gallbladder Neoplasms; Half-Life; Humans; Male; Middle Aged; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome

2005